AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $329,923,577 | -2.8% | 27,131,873 | +0.4% | 0.01% | 0.0% |
Q2 2023 | $339,426,679 | +13.9% | 27,024,417 | +0.6% | 0.01% | 0.0% |
Q1 2023 | $297,898,970 | -8.1% | 26,861,945 | +1.2% | 0.01% | -11.1% |
Q4 2022 | $324,033,510 | +20.0% | 26,538,371 | +2.6% | 0.01% | +12.5% |
Q3 2022 | $270,095,000 | -2.3% | 25,871,062 | +0.5% | 0.01% | 0.0% |
Q2 2022 | $276,363,000 | +13.7% | 25,732,089 | +0.3% | 0.01% | +33.3% |
Q1 2022 | $242,973,000 | -18.0% | 25,657,170 | +0.0% | 0.01% | -14.3% |
Q4 2021 | $296,202,000 | +26.7% | 25,645,184 | +4.7% | 0.01% | +16.7% |
Q3 2021 | $233,866,000 | -1.9% | 24,488,601 | -1.0% | 0.01% | 0.0% |
Q2 2021 | $238,392,000 | -1.1% | 24,729,400 | +1.4% | 0.01% | -14.3% |
Q1 2021 | $240,945,000 | -56.2% | 24,387,053 | +2.3% | 0.01% | -56.2% |
Q4 2020 | $550,591,000 | +68.2% | 23,845,433 | +2.8% | 0.02% | +45.5% |
Q3 2020 | $327,409,000 | -10.0% | 23,187,567 | -3.8% | 0.01% | -15.4% |
Q2 2020 | $363,620,000 | +63.2% | 24,112,736 | -0.0% | 0.01% | +44.4% |
Q1 2020 | $222,856,000 | -3.7% | 24,118,586 | +1.5% | 0.01% | +12.5% |
Q4 2019 | $231,414,000 | +23.9% | 23,759,160 | +2.0% | 0.01% | +14.3% |
Q3 2019 | $186,734,000 | -33.0% | 23,283,609 | +4.3% | 0.01% | -30.0% |
Q2 2019 | $278,687,000 | +3.4% | 22,330,661 | +12.7% | 0.01% | -9.1% |
Q1 2019 | $269,559,000 | +63.9% | 19,820,543 | +15.4% | 0.01% | +57.1% |
Q4 2018 | $164,507,000 | -19.0% | 17,171,997 | +2.2% | 0.01% | -12.5% |
Q3 2018 | $203,205,000 | -20.0% | 16,807,772 | +3.3% | 0.01% | -27.3% |
Q2 2018 | $254,082,000 | +7.9% | 16,266,464 | +3.9% | 0.01% | +10.0% |
Q1 2018 | $235,441,000 | +20.0% | 15,654,294 | +14.8% | 0.01% | +11.1% |
Q4 2017 | $196,204,000 | -2.0% | 13,634,785 | +2.7% | 0.01% | 0.0% |
Q3 2017 | $200,275,000 | +118.1% | 13,280,868 | +45.7% | 0.01% | +80.0% |
Q2 2017 | $91,821,000 | +48.2% | 9,118,246 | +5.0% | 0.01% | +66.7% |
Q1 2017 | $61,944,000 | +49.6% | 8,687,760 | +4.2% | 0.00% | +50.0% |
Q4 2016 | $41,419,000 | -29.7% | 8,333,811 | +4.7% | 0.00% | -33.3% |
Q3 2016 | $58,879,000 | +53.3% | 7,956,543 | +13.1% | 0.00% | +50.0% |
Q2 2016 | $38,404,000 | -30.2% | 7,033,500 | +8.1% | 0.00% | -50.0% |
Q1 2016 | $55,005,000 | -8.9% | 6,509,450 | +4.5% | 0.00% | 0.0% |
Q4 2015 | $60,408,000 | -86.1% | 6,227,567 | -66.5% | 0.00% | -75.0% |
Q3 2015 | $435,464,000 | +836.0% | 18,566,132 | +464.7% | 0.02% | +433.3% |
Q2 2015 | $46,526,000 | +67.6% | 3,288,076 | +28.9% | 0.00% | +50.0% |
Q1 2015 | $27,752,000 | +40.3% | 2,550,728 | +7.3% | 0.00% | +100.0% |
Q4 2014 | $19,783,000 | +87.5% | 2,377,689 | +34.1% | 0.00% | 0.0% |
Q3 2014 | $10,551,000 | +132.1% | 1,773,331 | +30.3% | 0.00% | – |
Q2 2014 | $4,546,000 | +78.3% | 1,361,170 | +10.5% | 0.00% | – |
Q1 2014 | $2,550,000 | -8.9% | 1,231,741 | +3.5% | 0.00% | – |
Q4 2013 | $2,798,000 | +10.5% | 1,190,481 | +9.1% | 0.00% | – |
Q3 2013 | $2,532,000 | -0.5% | 1,091,462 | -0.1% | 0.00% | – |
Q2 2013 | $2,546,000 | – | 1,092,697 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |